Stay updated with breaking news from Ellenk Ritchie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12.12.2023 - Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2 study shows that rusfertide ... Seite 1
Protagonist Reports Third Quarter 2023 Financial Results and Provides ...
Protagonist Therapeutics Announces Abstracts Selected for Oral and ...
Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral ...
02.11.2023 - Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral ...